Cargando…
Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial
BACKGROUND: Pre-exposure prophylaxis (PrEP) is a promising strategy to break COVID-19 transmission. Although hydroxychloroquine was evaluated for treatment and post-exposure prophylaxis, it is not evaluated for COVID-19 PrEP yet. The aim of this study was to evaluate the efficacy and safety of PrEP...
Autores principales: | Grau-Pujol, Berta, Camprubí-Ferrer, Daniel, Marti-Soler, Helena, Fernández-Pardos, Marc, Carreras-Abad, Clara, Andrés, Maria Velasco-de, Ferrer, Elisabet, Muelas-Fernandez, Magdalena, Jullien, Sophie, Barilaro, Giuseppe, Ajanovic, Sara, Vera, Isabel, Moreno, Laura, Gonzalez-Redondo, Eva, Cortes-Serra, Núria, Roldán, Montserrat, Arcos, Ana Artes-de, Mur, Isabel, Domingo, Pere, Garcia, Felipe, Guinovart, Caterina, Muñoz, Jose |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591593/ https://www.ncbi.nlm.nih.gov/pubmed/34781981 http://dx.doi.org/10.1186/s13063-021-05758-9 |
Ejemplares similares
-
Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: A structured summary of a study protocol for a multicentre, double-blind randomized controlled trial
por: Grau-Pujol, Berta, et al.
Publicado: (2020) -
Malaria prophylaxis approach during COVID-19 pandemic
por: Rodriguez-Valero, Natalia, et al.
Publicado: (2020) -
Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients
por: Camprubí, Daniel, et al.
Publicado: (2020) -
Correction: Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients
por: Camprubí, Daniel, et al.
Publicado: (2022) -
Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine()
por: Tejada Cifuentes, Francisco, et al.
Publicado: (2021)